Addressing manufacturing controls, cell and gene therapies experts and advisers will exchange practical insights and expectations on

• critical elements of establishing a robust CMC (Chemistry Manufacturing Controls) strategy,
• CQAs (Critical Quality Attributes),
• CPPs (Critical Process Parameters),
• key factors in easing the complexity of vector production,
• critical considerations on the sophistication of production processes and performance

for CGTP (cell and gene therapy products) in order to assure that production processes meet technical, regulatory, and cost-efficiency excellence for manufacturing safe ;